Unravelling the Role of KCTD Protein Family in the Clinical Management of Childhood Acute Lymphoblastic Leukemias

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

A transcriptomic analysis of bone marrow from B-ALL patients was performed by our research group for identifying novel protein/factor with a putative role of disease biomarker. Along with some already known B-ALL biomarkers, our analysis highlighted deregulation of some members of an emerging protein class denoted as KCTD (Potassium ChannelTetramerization Domain-containing proteins). Starting from our preliminary observations, and considering that KCTDs havenever been studied in ALL, we decided to study these proteins in B- and T-ALL affected pediatric patients, enrolled by our research group in collaboration with AORN Santobono-Pausilipon pediatric oncological hospital.Indeed, the present research program aims at opening a new scenario for the study of KCTD proteins in childhood leukemias. The final goal of the project will be to evaluate the translational relevance of selected deregulated KCTDs as novel biomarkers useful for B-ALL and T-ALL diagnostics, and patient management.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 1
Maximum Age: 18
Healthy Volunteers: t
View:

• Patients aged 1-18 years of both sexes diagnosed with B- ALL and T-ALL;

• Patients who will have signed the informed consent

Locations
Other Locations
Italy
IRCCS Synlab SDN
RECRUITING
Naples
Contact Information
Primary
Laura Pierri, MSC
direzionescientifica.irccssdn@synlab.it
0812408470
Time Frame
Start Date: 2020-03-02
Estimated Completion Date: 2025-07-31
Participants
Target number of participants: 80
Treatments
Pediatric acute lymphoblastic leukemia patients
pediatric patients of 1-16 years old affected by acute lymphoblastic leukemia
healthy subjects
cord blood from healthy donors that cannot be used for clinical purposes
Sponsors
Leads: IRCCS SYNLAB SDN
Collaborators: Santobono-Pausilipon Hospital

This content was sourced from clinicaltrials.gov